POINT OF CARE DIAGNOSTICS
POINT OF CARE DIAGNOSTIC DEVICE FOR THE DETECTION OF STIS
448 Million new cases of curable sexually transmitted infections (STIs) including syphilis, gonorrhoea, chlamydia and trichomoniasis occur annually throughout the world in adults aged 15-49 years. This does not include HIV and other STIs which continue to adversely affect the lives of individuals and communities worldwide. In developing countries, STIs and their complications rank in the top five disease categories for which adults seek health care. Public health campaigns have had little impact on incidence of disease as STI infection rates worldwide are rising rapidly.
Existing methods of laboratory testing are time consuming, with the risk of patients spreading disease whilst awaiting results. Furthermore, current technologies are unsuited to a Point of Care (POC) setting removing the benefits of immediate treatment.
Grey Innovation, along with MiniFab and the Royal Women’s Hospital conducted a feasibility study into the development of a new and improved STI diagnostic device. The device utilises nucleic acid (NA) amplification and detection testing to provide a portable, low cost and highly sensitive POC device. The device can also be developed to accommodate testing for drug resistance in the infective agent(s). Knowledge of drug resistance enables health workers to select appropriate treatments on the spot. This will vastly improve health impacts for patients and productivity impacts for health services.